NO20082483L - Use of complement pathway inhibitors for the treatment of ocular diseases - Google Patents

Use of complement pathway inhibitors for the treatment of ocular diseases

Info

Publication number
NO20082483L
NO20082483L NO20082483A NO20082483A NO20082483L NO 20082483 L NO20082483 L NO 20082483L NO 20082483 A NO20082483 A NO 20082483A NO 20082483 A NO20082483 A NO 20082483A NO 20082483 L NO20082483 L NO 20082483L
Authority
NO
Norway
Prior art keywords
factor
ocular diseases
treatment
complement pathway
pathway inhibitors
Prior art date
Application number
NO20082483A
Other languages
Norwegian (no)
Inventor
Zhengbin Yao
Sek Chung Fung
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38023865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082483(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20082483L publication Critical patent/NO20082483L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)

Abstract

Sammendrag Behandling av okulære sykdommer og tilstander ved å administrere en komplementveiinhibitor, spesielt en altemativ vei-inhibitor. Okulære sykdommer inkluderer aldersrelatert makuladegenerasjon, diabetisk retinopati og okulær angiogenese. En utførelsesform omfatter å administrere et anti-faktor D-antistoff i form av et helt antistoff, et Fab-fragment eller et enkelt domene-antistoff. Andre komplementkomponentinhibitorer som kan være nyttige i den foreliggende oppfinnelse inkluderer faktor H eller inhibitorer som mangler virkningen av properdin, faktor B, faktor Ba, faktor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9 eller C5b-9.Summary Treatment of ocular diseases and conditions by administering a complement pathway inhibitor, especially an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises administering an anti-factor D antibody in the form of an entire antibody, a Fab fragment, or a single domain antibody. Other complement component inhibitors which may be useful in the present invention include factor H or inhibitors lacking the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9 or C5b-9.

NO20082483A 2005-11-04 2008-06-03 Use of complement pathway inhibitors for the treatment of ocular diseases NO20082483L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73376305P 2005-11-04 2005-11-04
PCT/US2006/043103 WO2007056227A2 (en) 2005-11-04 2006-11-04 Use of complement pathway inhibitors to treat ocular diseases

Publications (1)

Publication Number Publication Date
NO20082483L true NO20082483L (en) 2008-08-01

Family

ID=38023865

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082483A NO20082483L (en) 2005-11-04 2008-06-03 Use of complement pathway inhibitors for the treatment of ocular diseases

Country Status (29)

Country Link
US (3) US8753625B2 (en)
EP (4) EP3299027A1 (en)
JP (7) JP2009514888A (en)
KR (6) KR20180002911A (en)
CN (2) CN101355956A (en)
AU (1) AU2006311803C1 (en)
BR (1) BRPI0619657A2 (en)
CA (2) CA2624393C (en)
CR (1) CR10041A (en)
DK (1) DK2500030T4 (en)
EC (1) ECSP088500A (en)
ES (1) ES2551202T5 (en)
HK (2) HK1175718A1 (en)
HU (1) HUE026423T2 (en)
IL (3) IL190547A (en)
MA (1) MA29976B1 (en)
MX (3) MX337061B (en)
MY (1) MY151064A (en)
NO (1) NO20082483L (en)
NZ (2) NZ567483A (en)
PH (1) PH12013501270B1 (en)
PL (1) PL2500030T5 (en)
PT (1) PT2500030E (en)
RU (2) RU2417099C2 (en)
SG (1) SG10201804008UA (en)
SI (1) SI2500030T2 (en)
UA (1) UA99591C2 (en)
WO (1) WO2007056227A2 (en)
ZA (2) ZA200803659B (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1713503E (en) 2004-02-10 2013-11-14 Nat Jewish Health Inhibition of factor b, the alternative complement pathway and methods related thereto
WO2006096561A2 (en) 2005-03-04 2006-09-14 Duke University Genetic variants increase the risk of age-related macular degeneration
ES2548700T3 (en) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibition of the alternative complement pathway for the treatment of traumatic brain injury, spinal cord injury and related conditions
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007056227A2 (en) 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
CN101563363B (en) 2006-06-21 2013-01-02 南卡罗来纳医疗大学研究发展基金会 Targeting complement factor H for treatment of diseases
PL3028716T3 (en) 2006-10-10 2021-03-08 Regenesance B.V. Complement inhibition for improved nerve regeneration
EP2097455B1 (en) 2006-11-02 2014-10-22 Genentech, Inc. Humanized anti-factor d antibodies
EP2236518B1 (en) 2007-03-14 2014-08-06 Alexion Cambridge Corporation Humaneered anti-factor B antibody
EP2129681A2 (en) * 2007-03-22 2009-12-09 Novartis Ag C5 antigens and uses thereof
WO2009029669A1 (en) * 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
AR066660A1 (en) 2007-05-23 2009-09-02 Genentech Inc PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
CA2704973A1 (en) * 2007-11-08 2009-05-14 Genentech, Inc. Anti-factor b antibodies and their uses
WO2009111701A2 (en) * 2008-03-06 2009-09-11 Case Western Reserve University Method of treating t cell mediated disorders
CR20170001A (en) * 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
AU2013200637B2 (en) * 2008-04-28 2015-07-16 Genentech, Inc. Humanized anti-Factor D antibodies and uses thereof
CA2730203C (en) * 2008-07-10 2016-12-13 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement antagonists and uses thereof
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
US8092013B2 (en) * 2008-10-28 2012-01-10 Johnson & Johnson Vision Care, Inc. Apparatus and method for activation of components of an energized ophthalmic lens
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
PL2391419T3 (en) 2009-01-29 2019-12-31 Forsight Vision4, Inc. Posterior segment drug delivery
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development Methods of stimulating liver regeneration
AU2010314931A1 (en) 2009-11-05 2012-06-21 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011113641A1 (en) 2010-02-12 2011-09-22 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Complement factor h for oxidative stress disease conditions
US20130058931A1 (en) 2010-03-11 2013-03-07 University Of Louisville Research Foundation, Inc. Methods of predicting and decreasing the risk of pregnancy loss
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
JP5986990B2 (en) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート Improved complement receptor 2 (CR2) targeting group
WO2011163412A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
SI2600812T1 (en) * 2010-08-05 2021-12-31 ForSight Vision4, Inc., Apparatus to treat an eye
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
EP2635704B1 (en) * 2010-11-01 2017-04-19 F. Hoffmann-La Roche AG Predicting progression to advanced age-related macular degeneration using a polygenic score
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2646821A4 (en) 2010-11-29 2015-09-23 Novelmed Therapeutics Inc Neoantibodies for diagnosing tissue injury
RU2639521C2 (en) * 2011-05-05 2017-12-21 ВЕЛЛСТАТ ИММЬЮНОТЕРАПЬЮТИКС, ЭлЭлСи Analogues of complement factor b and their application
EP4105224A1 (en) * 2011-05-11 2022-12-21 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and uses thereof
US10588879B2 (en) * 2011-08-01 2020-03-17 Aurin Biotech Inc. Treatment of age-related macular degeneration
EP3330288A1 (en) 2011-12-21 2018-06-06 Novartis AG Compositions and methods for antibodies targeting factor p
PL2817329T3 (en) * 2012-02-20 2019-07-31 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
US9540626B2 (en) 2012-03-19 2017-01-10 The Trustees Of The University Of Pennsylvania Regulator of complement activation and uses thereof
FR2988298A1 (en) * 2012-03-23 2013-09-27 Lfb Biotechnologies FACTOR H FOR ITS USE AS ANTIOXIDIZING MOLECULE
WO2013152020A1 (en) 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc Humaneered anti-factor b antibody
ES2584702T3 (en) * 2012-06-20 2016-09-28 Novartis Ag Complement path modulators and uses thereof
KR102073312B1 (en) 2012-06-27 2020-02-05 엘지전자 주식회사 Marker for diagnosing diabetic retinopathy and use thereof
CN102743371A (en) * 2012-07-26 2012-10-24 山东省眼科研究所 Medicine for treating retinal neovascular diseases
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CA2887050A1 (en) 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
EP3660033B9 (en) 2012-11-15 2022-06-22 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
BR112015018438A2 (en) * 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation c5 antibody and method for preventing and treating complement-related diseases
EP2970269B1 (en) 2013-03-14 2017-04-19 Novartis AG 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
CA2905496A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
CN105246438B (en) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 For conveying the ophthalmic implant of therapeutic substance
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
EP3019243A4 (en) 2013-07-12 2017-03-15 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
KR20160042438A (en) * 2013-08-12 2016-04-19 제넨테크, 인크. Compositions and method for treating complement-associated conditions
EP3054965B1 (en) * 2013-10-07 2021-04-14 Massachusetts Eye & Ear Infirmary Anti-factor d antibody for use in preventing or reducing retinal detachment
JP2016535042A (en) 2013-10-30 2016-11-10 ノバルティス アーゲー 2-Benzyl-benzimidazole complement factor B inhibitor and uses thereof
AU2014370404A1 (en) * 2013-12-24 2016-07-07 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
EP3110845A1 (en) 2014-02-27 2017-01-04 Allergan, Inc. Complement factor bb antibodies
US10179821B2 (en) 2014-05-01 2019-01-15 Genentech, Inc. Anti-factor D antibodies
BR122023024819A2 (en) 2014-06-12 2023-12-26 Ra Pharmaceuticals, Inc. USE OF A POLYPEPTIDE TO INHIBIT C5 CLEASE IN A CELLULAR SYSTEM
CN107106551A (en) 2014-08-08 2017-08-29 弗赛特影像4股份有限公司 The stabilization of receptor tyrosine kinase inhibitors and solvable preparation and its preparation method
BR112017003200B1 (en) * 2014-08-20 2023-12-26 Stichting Sanquin Bloedvoorziening FACTOR H ENHANCEMENT ANTIBODIES AND THEIR USES
EA201791029A1 (en) 2014-11-10 2017-12-29 Дженентек, Инк. ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
JP7261583B2 (en) 2015-09-24 2023-04-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for treating complement-mediated diseases
BR112018006810A2 (en) 2015-10-07 2018-10-23 Apellis Pharmaceuticals Inc dosage regimens
CN108513585A (en) 2015-10-30 2018-09-07 豪夫迈·罗氏有限公司 The method for measuring factor D activity and factor D inhibitor effect
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
CN108697759B (en) 2015-12-16 2022-08-02 Ra制药公司 Modulators of complement activity
US11072661B2 (en) 2015-12-23 2021-07-27 Sorbonne Universite Agents that inhibit the binding of CFH to CD11 b/CD18 and uses thereof
JP2019506159A (en) 2016-01-20 2019-03-07 ヴィトリサ セラピューティクス， インコーポレイテッド Compositions and methods for inhibiting factor D
PE20190209A1 (en) 2016-04-04 2019-02-07 Bioverativ Usa Inc COMPLEMENT ANTI-FACTOR BB ANTIBODIES AND USE OF THEM
UA124734C2 (en) 2016-06-14 2021-11-10 Рідженерон Фармасьютікалз, Інк. Anti-c5 antibodies and uses thereof
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
US11198725B2 (en) * 2017-01-30 2021-12-14 Alexion Pharmaceuticals, Inc. Monovalent anti-properdin antibodies and antibody fragments
EA201991876A1 (en) * 2017-02-10 2020-03-13 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания ANTIBODIES AGAINST FACTOR D AND THEIR APPLICATION
CN110831544B (en) 2017-04-07 2022-11-18 阿佩利斯制药有限公司 Long-acting compstatin analogs, dosing regimens for compositions thereof, and medical uses thereof
WO2018191548A2 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
CN111201246B (en) 2017-07-11 2023-10-27 亚力兄制药公司 Polypeptide binding complement component C5 or serum albumin and fusion protein thereof
WO2019075220A1 (en) * 2017-10-11 2019-04-18 Bioverativ Usa Inc. Methods of inducing complement activity
BR112020010916A2 (en) 2017-12-04 2020-11-17 Ra Pharmaceuticals, Inc modulators of complement activity
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
MX2020009152A (en) 2018-03-02 2020-11-09 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof.
AR117565A1 (en) 2018-04-03 2021-08-18 Ngm Biopharmaceuticals Inc BINDING AGENTS TO C3 AND METHOD OF USE OF THE SAME
AU2019266548A1 (en) * 2018-05-10 2021-01-07 Complement Therapeutics Limited Methods for assessing macular degeneration
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
JP2022524078A (en) 2019-03-08 2022-04-27 ラ ファーマシューティカルズ インコーポレイテッド Zircoplan as a deep tissue penetrating C5 inhibitor
CA3134614A1 (en) 2019-03-29 2020-10-08 Ra Pharmaceuticals, Inc. Complement modulators and related methods
US20220211799A1 (en) 2019-04-24 2022-07-07 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
AU2020313981A1 (en) 2019-07-17 2022-03-03 Gemini Therapeutics Sub, Inc. Factor H potentiating antibodies and uses thereof
KR102428619B1 (en) 2019-09-25 2022-08-04 대구가톨릭대학교산학협력단 Contact Lens Releasing Drug for Treating Retinopathy and Manufacturing Method Thereof
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Anti-interleukin-33 antibodies and uses thereof
CA3173325A1 (en) 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof
CN114686481B (en) * 2020-12-31 2023-08-15 北京键凯科技股份有限公司 Interference RNA for inhibiting CFD expression and preparation method and application thereof
TW202415387A (en) * 2022-06-30 2024-04-16 美商伊維希比奥公司 Sustained release silica hydrogel composites for treating ophthalmological conditions and methods of using same

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5022A (en) * 1847-03-20 Alfred stillman
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE68913658T3 (en) 1988-11-11 2005-07-21 Stratagene, La Jolla Cloning of immunoglobulin sequences from the variable domains
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP3068180B2 (en) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド Generation of heterologous antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
ATE160379T1 (en) 1990-10-29 1997-12-15 Chiron Corp BISPECIFIC ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF
EP1149913A1 (en) 1990-11-09 2001-10-31 GILLIES, Stephen D. Cytokine immunoconjugates
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992019973A1 (en) 1991-04-26 1992-11-12 Surface Active Limited Novel antibodies, and methods for their use
DE69231736T2 (en) 1991-05-14 2001-10-25 The Immune Response Corp., Carlsbad TARGETED DELIVERY OF GENES ENCODING IMMUNOGENIC PROTEINS
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
CA2103371C (en) 1991-06-05 2003-09-16 George Y. Wu Targeted delivery of genes encoding secretory proteins
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young Gene therapy using targeted viral vectors.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1993025788A1 (en) 1992-06-09 1993-12-23 Hoppe Ag Latch and lockset system
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
WO1994004670A1 (en) 1992-08-26 1994-03-03 President And Fellows Of Harvard College Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK0671923T3 (en) 1992-10-09 2001-08-13 Advanced Tissue Sciences Inc Liver reserve cells
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
DK0698097T3 (en) 1993-04-29 2001-10-08 Unilever Nv Production of antibodies or (functionalized) fragments thereof derived from Camelidae heavy chain immunoglobulins
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
WO2000053758A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5679564A (en) 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
DE69637481T2 (en) 1995-04-27 2009-04-09 Amgen Fremont Inc. Human antibodies to IL-8 derived from immunized Xenomae
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2230758A1 (en) 1995-09-08 1997-03-13 Genzyme Corporation Improved aav vectors for gene therapy
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
EP0904278A4 (en) 1996-03-22 1999-09-15 Human Genome Sciences Inc Apoptosis inducing molecule ii
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR20080059467A (en) 1996-12-03 2008-06-27 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
WO2001036432A2 (en) 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 18 human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
ATE335511T1 (en) 1997-08-26 2006-09-15 Amgen Fremont Inc A METHOD FOR INHIBITING COMPLEMENT ACTIVATION VIA AN ALTERNATIVE PATHWAY
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
CN1174993C (en) 1997-11-03 2004-11-10 人体基因组科学有限公司 VEGI, an inhibitor of angiogenesis and tumor growth
US6595142B2 (en) 1997-11-13 2003-07-22 M.C.M. Holding A/S Floor for a transport means and profiles for the construction thereof as well as a vehicle provided with such a floor
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
EP1481990B1 (en) 1997-11-21 2007-06-06 Genentech, Inc. A-33 related antigens and their pharmacological uses
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
CA2320625A1 (en) 1998-02-09 1999-08-12 Human Genome Sciences, Inc. 45 human secreted proteins
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
CA2321140C (en) 1998-02-20 2015-04-07 Tanox, Inc. Inhibitors of complement activation
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
ES2312205T3 (en) 1998-03-10 2009-02-16 Genentech, Inc. NEW POLYPEPTIDE AND NUCLEIC ACIDS THAT CODE IT.
JP2002523089A (en) 1998-08-27 2002-07-30 インサイト・ファーマスーティカルズ・インコーポレイテッド Protein transport-related molecules
EP1141285A2 (en) 1998-12-16 2001-10-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA01006330A (en) 1998-12-22 2002-07-02 Genentech Inc Methods and compositions for inhibiting neoplastic cell growth.
KR20060067983A (en) 1999-01-15 2006-06-20 제넨테크, 인크. Polypeptide variants with altered effector function
DE60045681D1 (en) 1999-03-11 2011-04-14 Merck Serono Sa VASCULAR ADHESION MOLECULES AND MODULATION OF THEIR FUNCTION
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2490909A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
AU2001249410A1 (en) 2000-03-23 2001-10-03 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation
ATE412185T1 (en) * 2000-04-29 2008-11-15 Univ Iowa Res Found DIAGNOSTICS AND THERAPEUTICS FOR MACULA DEGENERATION DISEASES
EP1309620A2 (en) 2000-06-23 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2416538A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2113516B1 (en) 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
CN1547590A (en) 2000-10-13 2004-11-17 ¸ Humanized anti-LT-beta-R antibodies
US20040077575A1 (en) * 2002-01-11 2004-04-22 Giordano Giovan Giacomo Inhibition of pathological angiogenesis in vivo
US6867189B2 (en) † 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
AR040778A1 (en) 2002-08-06 2005-04-20 Glaxo Group Ltd ALTERED ANTIBODIES OR FUNCTIONAL FRAGMENTS THAT BIND MAG (GLICOPROTEIN ASSOCIATED WITH HONEY).
WO2004022594A2 (en) 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
US7816497B2 (en) * 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
RU2232991C1 (en) 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Method for assay of functional activity of human complement factor d
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
JP2007527865A (en) * 2003-09-12 2007-10-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloid formed from proteins with various sequences
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
AU2005314461B2 (en) 2004-11-18 2012-02-02 The Rockefeller University Methods and compositions for treating ocular disorders
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
WO2006088950A2 (en) * 2005-02-14 2006-08-24 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
PL1951279T3 (en) * 2005-10-08 2017-12-29 Apellis Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
WO2007056227A2 (en) 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
EP2097455B1 (en) 2006-11-02 2014-10-22 Genentech, Inc. Humanized anti-factor d antibodies
AR066660A1 (en) 2007-05-23 2009-09-02 Genentech Inc PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT
CR20170001A (en) 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES

Also Published As

Publication number Publication date
RU2417099C2 (en) 2011-04-27
PL2500030T3 (en) 2015-12-31
NZ567483A (en) 2012-04-27
ZA201300649B (en) 2014-10-29
ES2551202T5 (en) 2018-11-30
WO2007056227A3 (en) 2007-10-11
HK1175718A1 (en) 2013-07-12
CN101355956A (en) 2009-01-28
EP2500030B1 (en) 2015-07-22
KR20150055628A (en) 2015-05-21
DK2500030T3 (en) 2015-10-19
HK1223106A1 (en) 2017-07-21
EP2500030B2 (en) 2018-08-08
KR20180002911A (en) 2018-01-08
JP2015157862A (en) 2015-09-03
IL190547A (en) 2017-03-30
WO2007056227A2 (en) 2007-05-18
JP2009514888A (en) 2009-04-09
RU2583927C2 (en) 2016-05-10
HUE026423T2 (en) 2016-05-30
EP3299027A1 (en) 2018-03-28
CR10041A (en) 2008-12-03
JP2009280626A (en) 2009-12-03
JP2015083609A (en) 2015-04-30
ECSP088500A (en) 2008-07-30
BRPI0619657A2 (en) 2011-11-08
US20180334495A1 (en) 2018-11-22
JP2019043963A (en) 2019-03-22
US20140335078A1 (en) 2014-11-13
MY151064A (en) 2014-03-31
PT2500030E (en) 2015-09-24
PL2500030T5 (en) 2019-02-28
JP2013049724A (en) 2013-03-14
SI2500030T1 (en) 2015-10-30
PH12013501270A1 (en) 2016-02-01
EP1942922A2 (en) 2008-07-16
AU2006311803C1 (en) 2015-05-14
MX360959B (en) 2018-11-23
CA2903896A1 (en) 2007-05-18
MA29976B1 (en) 2008-11-03
AU2006311803B2 (en) 2012-11-01
SG10201804008UA (en) 2018-06-28
EP2998318A1 (en) 2016-03-23
US8753625B2 (en) 2014-06-17
MX337061B (en) 2016-02-11
PH12013501270B1 (en) 2016-02-01
RU2010152367A (en) 2012-06-27
JP2017095522A (en) 2017-06-01
CA2624393A1 (en) 2007-05-18
CA2624393C (en) 2016-01-05
NZ594285A (en) 2013-02-22
MX2018014357A (en) 2020-09-14
EP2500030A3 (en) 2012-11-21
DK2500030T4 (en) 2018-10-29
EP1942922A4 (en) 2011-03-30
EP2500030A2 (en) 2012-09-19
SI2500030T2 (en) 2018-11-30
AU2006311803A1 (en) 2007-05-18
KR20170002684A (en) 2017-01-06
US20090214538A1 (en) 2009-08-27
IL190547A0 (en) 2008-11-03
KR20190026048A (en) 2019-03-12
KR20130137716A (en) 2013-12-17
KR101511787B1 (en) 2015-04-13
KR20080065693A (en) 2008-07-14
ES2551202T3 (en) 2015-11-16
ZA200803659B (en) 2009-07-29
IL263237A (en) 2018-12-31
CN107929731A (en) 2018-04-20
RU2008122341A (en) 2009-12-10
UA99591C2 (en) 2012-09-10
IL250772A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
NO20082483L (en) Use of complement pathway inhibitors for the treatment of ocular diseases
EA201791168A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR EYE DISEASES
PE20141563A1 (en) MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR PATHWAY INHIBITOR
WO2010126626A3 (en) Dual mechanism inhibitors for the treatment of disease
ES2530428T3 (en) Methods and compositions for the treatment of antibody-mediated neuropathies
CY1110435T1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES WITH RETINOL PRODUCER
CR11561A (en) Antigen binding proteins
CO6341486A2 (en) TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
CY1118902T1 (en) REGULATING THE ACTIVITY OF PONVRETROPHINS
DE602006019948D1 (en) COUPLED RECEPTOR FOR THE TREATMENT OF MACULAR GENERATION
NO20091700L (en) Florizine analogues as inhibitors of glucose co-transporter 2
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
CR20190403A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EA200870385A1 (en) INHIBITION OF TOXICITY ALPHA-SINUCLEINE
BRPI0211953B8 (en) monoclonal antibody or antigen-binding fragment that binds to c5 and c5a without the prevention of c5b formation, cell lineage, pharmaceutical composition, as well as in vitro method to inhibit c5a activity and in vitro diagnostic method
AR062840A1 (en) TUMOR THERAPY WITH AN ANTIBODY COMBINATION ANTI RECEIVER OF THE EPIDERMIC GROWTH FACTOR (HER2)
UA107929C2 (en) Antibodies against cxcr4 for the treatment of hiv infection
EA200800291A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPHTHALMOLOGICAL CONDITIONS
MY153669A (en) Ocular allergy treatments field of the invention
WO2006039327A3 (en) Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
TR201820051T4 (en) Use of Anti-factor XI Antibodies for Prevention or Treatment of Thrombus Formation
WO2008110885A3 (en) Methods of treating ophthalmic diseases
WO2012139069A3 (en) Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
EA201990988A1 (en) ANTIBODIES AGAINST CHIKV AND WAYS OF THEIR APPLICATION
ATE526953T1 (en) USE OF 5-HT7 RECEPTOR AGONISTS TO TREAT PAIN

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application